54,774 Shares of The Cooper Companies, Inc. $COO Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new position in The Cooper Companies, Inc. (NASDAQ:COO) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 54,774 shares of the medical device company’s stock, valued at approximately $3,096,000.

A number of other institutional investors have also modified their holdings of COO. Essential Partners LLC raised its stake in shares of Cooper Companies by 23.4% during the first quarter. Essential Partners LLC now owns 874 shares of the medical device company’s stock valued at $62,000 after acquiring an additional 166 shares in the last quarter. Basecamp Wealth Advisors LLC grew its stake in Cooper Companies by 20.8% in the first quarter. Basecamp Wealth Advisors LLC now owns 1,557 shares of the medical device company’s stock worth $111,000 after purchasing an additional 268 shares in the last quarter. Avalon Trust Co bought a new position in Cooper Companies in the second quarter worth approximately $25,000. Elevation Wealth Partners LLC increased its holdings in Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after purchasing an additional 375 shares during the period. Finally, New Mexico Educational Retirement Board increased its holdings in Cooper Companies by 4.3% during the 2nd quarter. New Mexico Educational Retirement Board now owns 9,700 shares of the medical device company’s stock worth $696,000 after purchasing an additional 400 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on COO. Citigroup reaffirmed a “neutral” rating and set a $60.00 target price (down from $80.00) on shares of Cooper Companies in a research report on Thursday, September 10th. Bank of America lowered Cooper Companies from a “buy” rating to a “neutral” rating and cut their price target for the company from $80.00 to $65.00 in a research note on Thursday, September 10th. Wall Street Zen downgraded Cooper Companies from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Robert W. Baird set a $61.00 price objective on shares of Cooper Companies and gave the stock a “neutral” rating in a research note on Thursday, September 10th. Finally, Weiss Ratings lowered shares of Cooper Companies from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, October 28th. Four investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Cooper Companies has a consensus rating of “Hold” and a consensus target price of $68.60.

Insider Buying and Selling at Cooper Companies

In related news, Director Lawrence Kurzius purchased 10,000 shares of the business’s stock in a transaction on Monday, September 14th. The shares were acquired at an average price of $53.91 per share, for a total transaction of $539,100.00. Following the purchase, the director owned 21,099 shares of the company’s stock, valued at $1,137,447.09. This trade represents a 90.10% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul A. Keel purchased 4,701 shares of the stock in a transaction on Friday, September 11th. The shares were purchased at an average cost of $53.18 per share, with a total value of $249,999.18. Following the transaction, the director owned 4,701 shares in the company, valued at $249,999.18. This trade represents a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 34,701 shares of company stock worth $1,880,039 over the last quarter. Insiders own 2.08% of the company’s stock.

Cooper Companies Stock Down 1.8%

NASDAQ COO traded down $1.15 during midday trading on Friday, hitting $62.36. 2,059,749 shares of the company traded hands, compared to its average volume of 3,311,420. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The company has a market cap of $11.86 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.41 and a beta of 0.83. The company’s 50-day simple moving average is $59.20 and its 200-day simple moving average is $68.61. The Cooper Companies, Inc. has a 52 week low of $51.01 and a 52 week high of $89.83.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.12 by $0.03. The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities research analysts forecast that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies announced that its board has approved a share repurchase program on Wednesday, September 9th that authorizes the company to repurchase $3 billion in outstanding shares. This buyback authorization authorizes the medical device company to purchase up to 22.7% of its shares through open market purchases. Share buyback programs are typically a sign that the company’s management believes its stock is undervalued.

Cooper Companies Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.